Published in PLOS One on 2026-03-09, this study is presented as an attributed evidence briefing. The excerpts below are the original researchers’ words, reproduced under their Creative Commons Attribution licence. Health Signal has selected the abstract and, where needed, opening background paragraphs; the complete methods, results, limitations and references remain in the linked paper.
Original authors: Yeshwas Abite Workneh, Desye Melese Sisay, Abebaw Fekadu, Abraham Tesfaye Bika, Alemu Tekewe Mogus, Tesfaye Sisay Tessema, Anoop Kumar
Source: PLOS One • DOI 10.1371/journal.pone.0344362
Read the complete primary study ↗ · Creative Commons Attribution licence
From the researchers
Abstract
Hepatitis B virus (HBV) contributes substantially to liver cancer, related mortality, and liver transplantation worldwide. The small hepatitis B surface antigen (HBsAg), particularly its major hydrophilic region (MHR) and the “a” determinant, is the primary target of serological diagnostics. However, escape mutant amino acid variants (EMAVs) within this region may reduce diagnostic specificity and sensitivity. In this study, publicly available HBsAg sequences were analyzed to determine the prevalence of EMAVs circulating in Ethiopia. We computationally designed three region-specific recombinant antigens (MeRPYS1, MeRPYS2, and MeRPYS3) by incorporating both wild-type and prevalent EMAV sequences. Linear and conformational B-cell epitopes, as well as T helper cell epitopes, were predicted for each antigen. Homology analyses were also performed to assess similarity to host proteins. Secondary and tertiary structures of the antigens were predicted to generate theoretical molecular models. Molecular docking analyses were performed to explore putative interaction patterns between each designed antigen and an anti-HBsAg-specific antibody. The predicted antigen–antibody complexes were further examined using molecular dynamics (MD) simulations to assess their theoretical stability and behavior over time. The resulting simulations provide predictive computational insights into possible antigenic features and interaction tendencies of the designed constructs. These findings are intended to generate testable hypotheses and should be interpreted cautiously, as the study is limited to in silico analyses and requires experimental validation.
Introduction
Viral hepatitis remains a significant global health burden, causing deaths primarily due to cirrhosis and liver cancer [1]. In 2015, viral hepatitis accounted for 1.34 million deaths, while in 2022 this figure was estimated at 1.3 million. These mortality estimates are comparable to those attributed to tuberculosis and exceed deaths caused by HIV. A majority (over 82%) of these deaths were attributed to chronic HBV infection [2,3].
In 2022, 254 million people were living with HBV, with 1.2 million new infections reported that year. Despite this substantial burden, only 13% of individuals with chronic HBV were diagnosed, and merely 3% of them received treatment [3]. These statistics highlight major gaps in HBV diagnosis and treatment.
HBV is a compact virus with a partially double-stranded DNA genome and is a member of the Hepadnaviridae family. First identified in 1965, HBV continues to be a major cause of both acute and chronic hepatitis. It spreads primarily through percutaneous, sexual, and parenteral transmission routes, targeting hepatocytes where it replicates and induces liver damage [4].
The genome of HBV is approximately 3.2 kb in length, consisting of relaxed-circular DNA with four overlapping open reading frames (ORFs) coding for essential viral proteins, C, P, S, and X. The S ORF produces the envelope proteins L-HBsAg, M-HBsAg, and S-HBsAg, with S-HBsAg being the most abundantly expressed protein. S-HBsAg forms both the viral envelope and sub-viral particles, which are present in much greater quantities than the infectious virus itself. Due to its abundance, S-HBsAg is a key focus in diagnostic, vaccine and therapeutic studies [5,6].
Reading this evidence
Use the full paper to check the study design, participant selection, comparator and outcome definitions before drawing a practical conclusion. An association does not by itself show cause and effect. A reported performance measure needs its denominator and uncertainty. A finding from a particular facility, sample or time period should retain that scope when it is discussed elsewhere.
This briefing makes the source accessible within the wider technology & industry desk. It does not assess an individual patient or certify a product. When considering relevance to another health system, examine the original authors’ account of context and limitations, then seek local implementation evidence. The related reporting below provides other studies to read alongside this one; it is a topic connection, rather than a claim that their results are directly comparable.
© 2026 Yeshwas Abite Workneh, Desye Melese Sisay, Abebaw Fekadu, Abraham Tesfaye Bika, Alemu Tekewe Mogus, Tesfaye Sisay Tessema, Anoop Kumar. Excerpts reproduced under CC BY. Selection, formatting and contextual notes by Health Signal. The researchers are the authors of the source study, not members of Health Signal’s staff.
Explore connected evidence
- Evidence brief: Identification of Candidate epitopes from nation-enriched sequences in the African swine fever virus genomes
- Evidence brief: Validation and limitations of the distress thermometer in identifying depression among metastatic breast cancer patients in Nigeria: Methodological challenges in depression-specific screening validation
- Evidence brief: Spatial clustering of esophageal cancer in central Oromia, Ethiopia: A spatial autocorrelation and scan statistics analysis
